Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXP

0.00
  • Tonix highlighted early commercial traction for fibromyalgia drug TONMYA, showing 1Q’26 net sales of USD 3.7 million.
  • Launch-to-date net sales totaled USD 5.1 million through March 31, 2026; more than 2,600 unique prescribers wrote prescriptions.
  • Cash and cash equivalents were about USD 185.5 million as of March 31, 2026; no debt; runway expected into early Q2’27.
  • Pipeline focus included TNX-4800 Lyme prevention program with an adaptive Phase 2 field study planned for 1H’27, pending FDA agreement.
  • Other planned studies cited TNX-1500 in organ transplant rejection in 2H’26, TNX-2900 in Prader-Willi syndrome in 1Q’27.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.